Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Technologies - Radioactive and Nonradioactive Probes: Probes for Neuroimaging

18F-Festron: A potential serotonin 5-HT3 receptor PET imaging agent

Neema Pithia, Neal Gulati, Min-Liang Pan, Evegueni Sevrioukov, Cristian Constantinescu and Jogeshwar Mukherjee
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 227;
Neema Pithia
1Brain Imaging and Psychiatry, UC Irvine, Irvine, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neal Gulati
1Brain Imaging and Psychiatry, UC Irvine, Irvine, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min-Liang Pan
1Brain Imaging and Psychiatry, UC Irvine, Irvine, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evegueni Sevrioukov
1Brain Imaging and Psychiatry, UC Irvine, Irvine, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristian Constantinescu
1Brain Imaging and Psychiatry, UC Irvine, Irvine, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jogeshwar Mukherjee
1Brain Imaging and Psychiatry, UC Irvine, Irvine, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

227

Objectives Ligand-gated ion channels, serotonin 5HT3 receptors are involved in a number of brain functions such as anxiety, neuronal excitation, and emesis. We have developed 18F-Festron (N-[(2-pyrolidinyl)methyl]-2,3-dimethoxy-5-(3’-18F-flouropropyl)benzamide) and used in vitro and in vivo methods to evaluate its potential as a possible PET imaging agent.

Methods In order to synthesize 18F-Festron, Festron Tosylate ((R) or (S)-N-[(1-BOC-2-pyrolidinyl)methyl]-2,3-dimethoxy-5-(3’-tosyloxypropyl)benzamide) was radiolabeled with 18F using Kryptofix and K2CO3 in acetonitrile at 96°C for 30 min and deprotected with trifluoroacetic acid at 80°C to yield (R) or (S)-18F-Festron. In vitro binding was carried out on 10 μm rat brain slices. MicroPET imaging in rats (after 0.5-1 mCi iv) was permormed on an Inveon scanner, and ex vivo autoradiographic studies on 40 μm brain slices were done on the rat brains. Ondansetron was used for nonspecific binding. Various brain regions were ascertained using the Optiquant Image analysis program, ASIPRO and PMOD.

Results 18F-Festron was synthesized in two-steps with modest yields in specific activities of >2Ci/μmol (60%CH3CN-0.1%Et3N in water, flow rate 2.5 ml/min- C18 semiprep). In vitro binding studies indicated weak selective binding to serotonergic regions in the hippocampus, possibly due to the low concentration of 5HT3 receptors. Low brain uptake of 18F-Festron was seen in the rat. Ex vivo MicroPET analysis displayed binding in numerous brain regions consistent with 5HT3 receptor binding. With respect to the cerebellum, ex vivo microPET ratios were: striatum = 3.3; hypothalamus = 2.2; hippocampus = 1.8; area postrema = 2.4 while autoradiographic ratios were 14, 9, 4 and 6 respectively.

Conclusions 18F-Festron exhibited a unique binding profile to rat brain regions known to contain significant amounts of 5HT3 receptors. Efforts are currently underway to increase brain permeability and fully characterize the binding of 18F-Festron to 5HT3 receptors

Back to top

In this issue

Journal of Nuclear Medicine
Vol. 52, Issue supplement 1
May 2011
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
18F-Festron: A potential serotonin 5-HT3 receptor PET imaging agent
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
18F-Festron: A potential serotonin 5-HT3 receptor PET imaging agent
Neema Pithia, Neal Gulati, Min-Liang Pan, Evegueni Sevrioukov, Cristian Constantinescu, Jogeshwar Mukherjee
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 227;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
18F-Festron: A potential serotonin 5-HT3 receptor PET imaging agent
Neema Pithia, Neal Gulati, Min-Liang Pan, Evegueni Sevrioukov, Cristian Constantinescu, Jogeshwar Mukherjee
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 227;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Technologies - Radioactive and Nonradioactive Probes: Probes for Neuroimaging

  • Comparison of cell uptake of fluorine-18 labeled (2S,4R)-4-fluoro-glutamine (FGln) and (2S,4R)-4-fluoro-glutamic acid (FGlu)
  • Identification of the key characteristics of successful PET neuroimaging probes
  • An imaging study to evaluate the D2 receptor activities and safety of I-123-IBZM SPECT in the differential diagnosis of Parkinsonian syndromes
Show more Molecular Targeting Technologies - Radioactive and Nonradioactive Probes: Probes for Neuroimaging

Probes for Neuroimaging

  • Discovery of two novel, selective agonist radioligands as PET imaging agents for the M1 muscarinic acetylcholine receptor
  • Imaging synaptic density with novel 18F-labeled radioligands for synaptic vesicle protein-2A (SV2A): synthesis and evaluation in nonhuman primates
  • Imaging the Receptor for Advanced Glycation Endproducts with [18F]RAGER
Show more Probes for Neuroimaging

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire